CareDx (CDNA) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
CareDx Reports Fourth Quarter and Full Year 2020 Results
February 24, 2021 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2020.
Recent Highlights:
Achieved total revenue of $58.6 million for the three months ended December 31, 2020, increasing 64% over prior year fourth quarterDelivered record full year revenue of $192.2 million, an increase of 51% compared with full year 2019... More


